Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle

Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle

Abstract Cyclin dependent kinase 2 (CDK2) regulates cell cycle and is an emerging target for cancer therapy. There are relatively small numbers of tumor models that exhibit strong dependence on CDK2 and undergo G1 cell cycle arrest following CDK2 inhibition. The expression of P16INK4A and cyclin E1...

Full description

Saved in:
Bibliographic Details
Main Authors: Vishnu Kumarasamy, Jianxin Wang, Michelle Roti, Yin Wan, Adam P. Dommer, Hanna Rosenheck, Sivasankar Putta, Alec Trub, John Bisi, Jay Strum, Patrick Roberts, Seth M. Rubin, Costakis Frangou, Karen McLean, Agnieszka K. Witkiewicz, Erik S. Knudsen
Format: Article
Language:English
Published: Nature Portfolio 2025-02-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-025-56674-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41467-025-56674-4

Similar Items